Description
Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with cancer and nearly 7 million people die. The most common cancers affecting the world include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder.
This Kalorama Information report – The World Market for Cancer Therapeutics and Biotherapeutics – focuses on several segments for cancer treatment. The report covers both currently marketed and late stage development cancer products. Revenues for each current market segment were generated using dollar and unit sales for each product.
The following approaches to cancer therapeutics are covered in the report:
- Biotherapeutics
- Monoclonal Antibodies
- Interleukins/ Interferons
- Kinases and Other Treatments
- Chemotherapy
- Alkylating Agents
- Antimetabolites
- Cytotoxic Agents
- Plant Derivatives
- Hormone Therapy
- Corticosteroids
- Hormone Antagonists/ Antagonists
- Aromatase Inhibitors
- SERMS
The report includes market share by type of cancer and market share by company for each of the three major segments. It also includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview, description of products on the market, list of products in late-stage development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.
A Primary Research Effort
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level.
Coverage of the Most Recent Product and Trends
The base year for data was 2008. Historical data was provided for the years 2004 through 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2004-2008, 2009-2013 and 2004-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends. Some of the trends that affected this market include the following:
- Insurance and Reimbursement
- Drug Costs
- Personalized Medicine
- Alliances, Acquisitions and Licensing Agreements
- Alcohol’s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Marketing and Distribution Trends
- Geographical Trends
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
Profiles of Twelve Key Competitors
As part of its comprehensive coverage, the following companies are profiled:
- AstraZeneca (coverage of Arimidex, Casodex, Faslodex, Zoladex, Iressa, Nolvadex and other products)
- Biogen IDEC (coverage of Rituxan and other products)
- Bristol-Myers Squibb (coverage of Erbitux, Taxol, Ixempra, Sprycel and other products)
- Eli Lilly (coverage of Alimta, Gemzar and other products)
- Genentech (coverage of Avastin, Herceptin, Rituxan )
- Johnson & Johnson (coverage of Doxil, Velcade, Leustatin)
- Merck & Company (coverage of Zolinza and other products)
- Novartis (coverage of Femara, Gleevec/Glivec, Tasigna, Sandostatin, Proleukin, Afinitor and other products)
- Pfizer (coverage of Camptosar and Sutent)
- Roche (coverage of Xeloda, Avastin, MabThera, Herceptin, Tarceva and pipeline drugs)
- Sanofi-Aventis (coverage of Taxotere, Eloxatine and others)
- Schering-Plough (coverage of Intron A, Timodar/Temodal, Caelyx/Doxil and pipeline plans)
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION
What is Cancer
Biochemistry of Cancer Cells
Carcinogen Metabolism
Causes of Cancer Growth
Environmental Factors, DNA, RNA
Cellular Oncogenes
Tumor Suppressor Genes
History and Growth of the Cancer Treatment Market
Growth of Cancer Development
Industry Structure
Product Segments and Technology
Chemotherapy: At a Glance
Hormone Therapy: At A Glance
Biotherapy: AT a Glance
Radiation Therapy: At a Glance
Demographics and Statistics
Global Cancer Statistics
Demographics
Aging Population
Life Expectancy and Cancer
Description of Cancers
Bladder Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Esophageal Cancer
Head and Neck
Kidney
Leukemia
Liver
Lung Cancer
Lymphoma
Melanoma
Multiple Myeloma
Neuroblastoma
Ovarian Cancer
Pancreas
Prostate Cancer
Stomach Cancer
CHAPTER THREE: CHEMOTHERAPY
Overview
Product Descriptions and Examples
Alkylating Agents
Antimetabolites
Cytotoxic Agents
Plant Derivatives
Market Size and Growth
Markets by Product Type
Markets by Geographical Segments
U.S. Market
European Market
Japan Market
ROW Market
Market Data by Indication
Competitive Analysis
CHAPTER FOUR: HORMONE THERAPY
Overview
Product Descriptions and Examples
Corticosteroids
Synthetic Corticosteroids
Hormone Agonists and Antagonists
Estrogens
Androgens
Antiestrogens
Antiandrogens
Gonadotropin-releasing Hormone Analogues
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Market Size and Growth
Markets by Product Type
Markets by Geographical Segments
U.S. Market
Europe Market
Japan Market
ROW Market
Market Data by Indication
Competitive Analysis
CHAPTER FIVE: BIOTHERAPEUTICS
Overview
Product Descriptions and Examples
Monoclonal Antibodies
Avastin (bevacizumab)
Campath (alemtuzumab)
Erbitux (cetuximab)
Herceptin (trastuzumab)
Mylotarg (gemtuzumab ozogamicin)
Panorex (edrecolomab)
Rituxan (rituximab)
Vectibix (panitumumab)
Interleukins/Interferons
Alferon-N
Infergen
Intron A
Proleukin
Roferon A
Other Biotherapy
Antisense Oligonucleotides
Apoptosis
Growth Factors
Methylation
P53
Ras Protein Drugs
Regulatory Enzymes
Proteasome Inhibitors
Radioimmunotherapy
Market Size and Growth
Markets by Product Type
Markets by Geographical Segments
U.S. Market
Europe Market
Japan Market
ROW Market
Market Data by Indication
Competitive Analysis
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
Overview
Total Market Size and Forecast
Competitive Landscape
CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
Introduction
Insurance and Reimbursement Issues
Cancer Drug Costs
Personalized Medicine
Targeted Cancer Therapy
Pharmacogenomics
Alliances Acquisitions and Licensing Agreements
Patient-Reported Outcomes
Alcohol’s Affect on Cancer Incidence
Healthy Lifestyles Continue to Show Promise for Cancer Prevention
Possibility for a Healthier U.S. Population
Cancer Trends
Marketing and Distribution Trends
Geographical Trends
United States
Europe
Japan
Elderly Clinical Trial Involvement
Late-Stage Drug Development Trends
CHAPTER EIGHT: CORPORATE PROFILES
Introduction
AstraZeneca plc
Biogen IDEC, Inc.
Bristol-Myers Squibb Company
Eli Lilly & Company
Genentech, Inc.
Johnson & Johnson
Merck & Company, Inc.
Novartis AG
Pfizer, Inc.
Roche
Sanofi-Aventis
Schering-Plough Corporation
CHAPTER NINE: COMPANY DIRECTORY
LIST OF EXHIBITS
EXECUTIVE SUMMARY
Table 1-1 World Cancer Treatment Market, 2004-2013
Figure 1-1 World Cancer Treatment Market, 2004-2013
INTRODUCTION
Table 2-1 Viruses Associated with Cancer in Humans
Table 2-2 Cancer Therapy Approvals per Year in the United States, 1970-2008
Figure 2-1 Cancer Therapy Approvals per Year in the United States, 1970-2008
Table 2-3 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
Figure 2-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
Table 2-4 Cancer Incidence and Mortality by Country 2007
Figure 2-3 Cancer Incidence by Country 2007
Figure 2-4 Cancer Deaths by Country 2007
Table 2-5 Total Cancer Incidence by Sex and Country, 2007
Figure 2-5 Total Cancer Incidence by Sex and Country, 2007
Table 2-6 World Population by Selected Geographical Region, 2007 – 2050
Figure 2-6 World Population by Selected Geographical Region, 2007-2050
Table 2-7 Estimated World Population by Age and Geographical Region, 2007
Figure 2-7 Estimated World Population by Age and Geographical Region, 2007
Table 2-8 Percent Population Over 65 by Year and Region
Figure 2-8 Estimated World Population by Age, 2007 and 2050
Table 2-9 Average Life Expectancy in Years by Country 1980 and 2008
Figure 2-9 Average Life Expectancy in Years by Country 1980 and 2008
Table 2-10 United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004
Table 2-11 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004
Figure 2-12 Approved Cancer Therapies in the United States by Indication
Table 2-10 Types Of Leukemia
Table 2-11 Types Of Primary Lung Cancer
Table 2-12 Classification Of Non-hodgkin’s Lymphomas
Table 2-13 Malignant Conditions Of The Skin
CHEMOTHERAPY
Table 3-1 Leading Products, 2008
Table 3-2 Newly Approved Chemotherapy Agents and Newly Approved Indications, 2007 through 2009
Table 3-3 World Chemotherapy Market, 2004-2013
Figure 3-1 World Chemotherapy Market, 2004-2013
Table 3-4 World Chemotherapy Market, Market by Product Classification, 2004-2013
Figure 3-2 World Chemotherapy Market
Figure 3-3 World Chemotherapy Market
Figure 3-4 World Chemotherapy Market
Figure 3-5 World Chemotherapy Market
Figure 3-6 World Chemotherapy Market
Figure 3-7 World Chemotherapy Market
Table 3-5 World Chemotherapy Market
Figure 3-8 World Chemotherapy Market
Table 3-6 World Chemotherapy Market, Leading Suppliers Shares by Market Revenues, 2008
Figure 3-9 World Chemotherapy Market, Leading Suppliers Market Share, 2008
HORMONE THERAPY
Table 4-1 Leading Products, 2008
Table 4-2 Newly Approved Hormone Cancer Therapies and Additional Indications 2007 through 2009
Table 4-3 World Hormone Therapy Market, 2004-2013
Figure 4-1 World Hormone Therapy Market, 2004-2013
Table 4-4 World Hormone Therapy Market, Market by Product Classification, 2004-2013
Figure 4-2 World Hormone Therapy Market, Market by Product Classification Revenues, 2004-2013
Figure 4-3 World Hormone Therapy Market, Market by Product Classification and Percent Distribution, 2004-2013
Figure 4-4 World Hormone Therapy Market, Market by Product Classification and Percent Market Share, 2008
Figure 4-5 World Hormone Therapy Market, Market by Product Classification and Percent Market Share, 2013
Figure 4-6 World Hormone Therapy Market
Figure 4-7 World Hormone Therapy Market
Table 4-5 World Hormone Therapy Market
Figure 4-8 World Hormone Therapy Market
Table 4-6 World Hormone Therapy Market, Leading Suppliers Shares by Market Revenues, 2008
Figure 4-9 World Hormone Therapy Market, Leading Suppliers Market Share, 2008
BIOTHERAPEUTICS
Table 5-1 Leading Products, 2008
Table 5-2 Newly Approved Biological Therapies and Additional Indications, 2007 through March 2009
Table 5-3 World Cancer Biotherapeutics Market, 2004-2013
Figure 5-1 World Cancer Biotherapeutics Market, 2004-2013
Table 5-4 World Cancer Biotherapeutics Market Market by Product Type, (Monoclonal Antibodies, Interleukins/ Interferons, Other) 2004-2013
Figure 5-2 World Cancer Biotherapeutics Market, Market by Product Classification (Monoclonal Antibodies, Interleukins/ Interferons, Other) OtherRevenues, 2004-2013
Figure 5-3 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Distribution, 2004-2013
Figure 5-4 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Market Share, 2008
Figure 5-5 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Market Share, 2013
Figure 5-6 World Cancer Biotherapeutics Market
Figure 5-7 World Cancer Biotherapeutics Market
Table 5-5 World Cancer Biotherapeutics Market
Figure 5-8 World Cancer Biotherapeutics Market
Table 5-6 World Biotherapeutics Market, Leading Suppliers Shares by Market Revenues, 2008
Figure 5-9 World Cancer Biotherapeutics Market, Leading Suppliers Market Share, 2008
WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
Table 6-1 World Cancer Market Market by Product Type, 2004-2013
Figure 6-1 World Cancer Market, Market by Product Type Revenues, 2004-2013
Figure 6-2 World Cancer Market, Market by Product Type and Percent Distribution, 2004-2013
Figure 6-3 World Cancer Market, Market by Product Type and Percent Market Share, 2008
Figure 6-4 World Cancer Market, Market by Product Type and Percent Market Share, 2013
Table 6-2 World Cancer Market, Top Five Suppliers Shares by Market Revenues, 2008
Figure 6-5 World Cancer Market, Top Five Suppliers Market Share, 2008 Issues and Trends Affecting the Cancer Market
ISSUES AND TRENDS AFFECTING THE CANCER MARKET
Table 7-1 Obesity Rates by State
Table 7-2 Select Products in Development by Product Name
Figure 7-1 Late Stage Cancer Compounds in Development for Major Indications
CORPORATE PROFILES
Figure 8-1 Late stage Cancer Therapies in Development for Leading Companies
